靶向mTORC1抑制促炎T细胞分化并改善大动脉炎
用雷帕霉素或RNA干扰阻断mTORC1可减少促炎T细胞频率并改善人源化TAK嵌合体小鼠的血管炎,提示靶向mTORC1是TAK的潜在治疗策略。
要点
- TAK患者CD4+ T细胞mTORC1活性显著升高,与促炎T细胞频率和疾病活动相关。
- 雷帕霉素或RNA干扰阻断mTORC1可减少Th1/Th17分化并改善人源化小鼠血管炎。
- mTORC1高活性是TAK促炎T细胞异常分化的关键细胞内在机制。
核心结论
- mTORC1高活性是TAK患者促炎T细胞自发异常分化的关键细胞内在机制,靶向mTORC1是有前景的TAK治疗策略。
研究设计与样本
- 使用雷帕霉素和慢病毒调控相关蛋白短发夹RNA阻断mTORC1活性。
- 建立人动脉-NSG小鼠嵌合体模型代表人类TAK,用于靶向mTORC1治疗实验。
主要发现
- TAK CD4+ T细胞选择性预置mTORC1高活性(P < 0.001),导致Th1和Th17细胞自发异常分化(P < 0.001)。
- 循环CD4+ T细胞mTORC1高活性预测TAK患者促炎T细胞频率升高和疾病活动(P < 0.001)。
- 雷帕霉素阻断mTORC1有效消除Th1和Th17细胞异常分化(P < 0.01)并改善人源化TAK嵌合体血管炎(P < 0.001)。
- RNA干扰抑制mTORC1足以降低促炎T细胞频率(P < 0.01)并限制TAK疾病进展(P < 0.01)。
临床怎么用
- mTORC1活性可作为TAK疾病活动和促炎T细胞频率的预测指标。
- 雷帕霉素或RNA干扰靶向mTORC1可能成为TAK的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Takayasu arteritis (TAK) is a progressive autoimmune large vessel vasculitis with infiltration of proinflammatory T cells, with a largely unknown etiology. This study was undertaken to explore the involvement of mechanistic target of rapamycin (mTOR) in proinflammatory T cell differentiation and disease progression in TAK. METHODS: Ninety-five patients with TAK, 26 patients with small vessel vasculitis, and 40 healthy donors were enrolled. Naive and memory CD4+ T cells were activated with anti-CD3/CD28 beads and analyzed for lineage differentiation. The mTORC1 activity was determined by quantifying intracellular phospho-S6 kinase 1 and phospho-S6 ribosomal protein. Rapamycin and lentiviral regulatory-associated protein of mTOR short hairpin RNA were used to block mTORC1 activity. Human artery-NSG mouse chimeras representing human TAK were established for targeting mTORC1 in disease treatment. RESULTS: TAK CD4+ T cells were selectively prepositioned with hyperactivity of mTORC1 (P < 0.001), resulting in spontaneous maldifferentiation of Th1 and Th17 cells (P < 0.001). Activity of mTORC1high in circulating CD4+ T cells predicted elevated frequencies of proinflammatory T cells and active disease in TAK patients (P < 0.001). Blockade of mTORC1 with rapamycin efficiently abrogated the maldifferentiation of Th1 and Th17 cells (P < 0.01) and ameliorated vasculitis in humanized TAK chimeras (P < 0.001). Inhibition of mTORC1 using RNA interference technology is sufficient to reduce proinflammatory T cell frequencies (P < 0.01) and restrict TAK disease progression in vivo (P < 0.01). CONCLUSION: Our findings indicate that hyperactivity of mTORC1 is a critical cell-intrinsic mechanism underlying spontaneous maldifferentiation of proinflammatory T cells in TAK patients. Targeting mTORC1 is a promising therapeutic strategy against TAK.
引用
- Zhang J, Zhao L, Wang J, et al. Targeting Mechanistic Target of Rapamycin Complex 1 Restricts Proinflammatory T Cell Differentiation and Ameliorates Takayasu Arteritis. Arthritis Rheumatol. 2019. PMID: 31430047. doi:10.1002/art.41084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。